Insider buying last 90 days
No open-market insider purchases were filed for JNJ in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every JNJ insider filing, plotted on the chart in Gekko.Open JNJ in Gekko
NYSE: JNJ
Johnson & Johnson (JNJ) Stock Analysis & Forecast
$269.99−0.23 (−0.1%)
Close on Sep 18, 2026. Page updated Sep 19, 9:14 pm ET.
Gekko Brief
AI summaryJohnson & Johnson closes at $269.99, little changed on the day, and sits above both its 50-day average of $263.29 and its 200-day average of $238.66, with the shorter average above the longer one. The GekkoIndex reads 55.3, placing the stock in the Neutral zone. Shares trade 2.7% below Gekko Fair Value of $277.59, within the 52-week range of $173.33 to $281.07.
Coverage this week centers on legal and portfolio matters tied to J&J's former consumer unit, Kenvue: a Philadelphia jury found Kenvue not liable in sunscreen cancer lawsuits, while separate coverage weighs J&J against Kenvue as a dividend holding, noting J&J's 64 consecutive dividend increases alongside talc-related legal liabilities. Institutional filings show Nykredit A/S taking a $235.8 million position in JNJ in the second quarter, while Smith Chas P & Associates trimmed its stake by 2.6% over the same period. Separately, CEO Joaquin Duato was elected to PepsiCo's board, effective 1 December 2026, and J&J presented at the Deutsche Bank 2026 Healthcare Summit.
Over the next 20 trading days, the main marker is the 13 October earnings date, 23 days away, falling inside a typical 20-day holding window; the last report on 15 July beat estimates ($2.90 versus $2.84) with a -1.5% reaction. Analyst consensus across 18 firms stands at 14 buy and 4 hold ratings, with a $277.91 price target implying 2.9% upside. Seasonally, this stretch has averaged +0.5% over five years, rising in 2 of them.
Written by AI and checked automatically against the figures on this page. Generated Sep 20, 2026 from the data above.
Price vs fair value
Close $269.99200-day averageGekko Fair Value $277.59
Key stats
- Market cap
- $650.6B
- P/E ratio
- 31
- Forward P/E
- 20.9
- EPS, TTM
- $8.73
- Revenue, TTM
- $97.93B
- Profit margin
- 21.5%
- Dividend yield
- 1.96%
- Beta
- 0.24
- Volume
- 15.93M avg 6.32M
- 1-year return
- +52.4%
- Typical daily move
- ±2%
- Typical 20-day move
- ±3.4%
- 50-day average
- $263.29
- 200-day average
- $238.66
- Next earnings
- Oct 13 before open
- Shares outstanding
- 2.41B
Johnson & Johnson swing-trade checklist
Johnson & Johnson scores 1 supportive, 3 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
1 supportive3 mixed1 headwind
- Trendsupportive
Above 50 and 200-day
Close $269.99 is above the 50-day ($263.29) and 200-day ($238.66) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexmixed
55.3, Neutral
Reading 55.3 is in the Neutral zone.
See the GekkoIndex - Fair valuemixed
2.7% below
Price is within 5% of Gekko Fair Value (2.7% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 23 days
Reports on Oct 13, 2026, 23 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalitymixed
+0.5% on average
From this point in the calendar, the next 20 trading days averaged +0.5% over 5 years, rising in 2 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Johnson & Johnson stock chart and price history
Johnson & Johnson closed at $269.99 on Sep 18, 2026, +52.4% over the past year, inside a 52-week range of $173.33 to $281.07.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −1.3%
- 3 months
- +18.2%
- 6 months
- +13.6%
- 1 year
- +52.4%
The full JNJ chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open JNJ in Gekko
Follow Johnson & Johnson through every session
Put JNJ on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track JNJ in GekkoFree for 7 days. No credit card required.
About Johnson & Johnson
Johnson & Johnson operates as a holding company centered on healthcare, covering the research, development, manufacturing, and sale of related products. It is best known for its broad reach across medical fields rather than a single product line, spanning treatments and devices used in patient care.
The business is structured into two segments. Innovative Medicine covers areas such as immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolic conditions, and pulmonary hypertension. MedTech supplies products for interventional solutions, orthopaedics, surgery, and vision, forming a separate line of offerings within the company.
Johnson & Johnson traces its founding back to 1887, established by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. It is headquartered in New Brunswick, New Jersey, and its shares are listed on the NYSE under the ticker JNJ.
- Listed
- NYSE
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Website
- jnj.com
Johnson & Johnson GekkoIndex: the smart money zone
Johnson & Johnson’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 55.3, in the Neutral zone, down 3.1 points over five sessions.
55.3Neutral
Down 3.1 points over five sessions.
Reading for Sep 18, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 35 | +0.1% | +0.2% | ||
| Accumulation | 162 | +0.4% | +1.5% | ||
| Neutral (current zone) | 379 | +0.4% | +2.0% | ||
| Distribution | 83 | +0.8% | +2.1% | ||
| Selling | 3 | Too few readings yet | |||
Average JNJ share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.2% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the JNJ price, zone by zone.Track JNJ in Gekko
Is Johnson & Johnson stock overvalued? Gekko Fair Value
Johnson & Johnson trades 2.7% below Gekko Fair Value of $277.59, so the shares are about fair value on Gekko’s estimate.
Gekko’s own estimate of what Johnson & Johnson shares are worth, recalculated every trading day.
$277.59
Gekko Fair Value, Sep 19, 2026
2.7% below fair value · About fair value
Gekko Fair Value on every chart, with the gap to price updating daily.Open JNJ in Gekko
Johnson & Johnson insider and Congress trading
No open-market insider purchases were filed for Johnson & Johnson, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in JNJ were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for JNJ, plotted on the chart in Gekko.Open JNJ in Gekko
Buybacks
Johnson & Johnson has been buying back its own shares.
- Bought back, quarter ended Jun 28, 2026
- $221.0M
- As a share of market cap
- 0.03%
- Trailing four quarters
- $8.08B
From company filings.
Hedge funds and billionaires quarter ended Mar 31
0of the funds Gekko tracks hold JNJ.
0added0opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko
Johnson & Johnson earnings: next date and track record
Johnson & Johnson reports on Oct 13, 2026, before the open (23 days away), and beat the EPS estimate in 7 of its last 8 reports.
Next earnings report
Oct 13, 2026
Expected before the open, 23 days away
- EPS estimate
- $2.85
- Revenue estimate
- $25.33B
7 of 8reports beat the EPS estimate
±1.3%average move across the report
5 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Jul 15, 2026 AI summary
- What they said
- JNJ reported Q2 2026 operational sales growth of 5.6%, with revenues exceeding $25 billion, putting the company on track to surpass $100 billion in annual revenue for the first time. Excluding STELARA, growth was double digits. Innovative Medicine grew 6.8% operationally with DARZALEX delivering $4B+ in sales, up ~18%. New launches ICOTYDE, INLEXZO, and RYBREVANT showed strong early momentum, with ICOTYDE surpassing 10,000 patients initiated.
- Guidance
- Management raised full-year 2026 guidance following a top and bottom line beat, targeting over $100 billion in annual revenue. Leadership expressed confidence in accelerating momentum into 2027, with line of sight to double-digit growth by end of the decade and oncology sales projected to exceed $50 billion by 2030.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Jul 15, 2026 | $2.90 est $2.84 | $25.31B est $25.06B | −1.5% |
| Apr 14, 2026 | $2.70 est $2.68 | $24.06B est $23.61B | +0.3% |
| Jan 21, 2026 | $2.46 est $2.46 | $24.56B est $24.15B | +0.1% |
| Oct 14, 2025 | $2.80 est $2.76 | $23.99B est $23.76B | +0.1% |
| Jul 16, 2025 | $2.77 est $2.68 | $23.74B est $22.85B | +5.0% |
| Apr 15, 2025 | $2.77 est $2.58 | $21.89B est $21.56B | −0.3% |
| Jan 22, 2025 | $2.04 est $1.99 | $22.52B est $22.43B | −1.0% |
| Oct 15, 2024 | $2.42 est $2.21 | $22.47B est $22.17B | +1.7% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Johnson & Johnson stock forecast and analyst price targets
Analysts’ average 12-month price target for Johnson & Johnson is $277.91, +2.9% from the last close, from 18 firms rating the stock in the last 90 days.
$277.91consensus 12-month target, +2.9% from the last close
Now $269.99Avg $277.91
Low $260High $320
Each firm’s latest rating in the last 90 days: 18 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 18 | Scotiabank | $305 | +13.0% |
| Sep 16 | RBC Capital | $287 | +6.3% |
| Sep 14 | TD Cowen | $300 | +11.1% |
| Sep 11 | DBS | $270 | 0.0% |
| Sep 10 | HSBC | $320 | +18.5% |
+2.0%average 20-day move after past Neutral readings
+0.5%average move over the next 20 trading days in the last 5 years
±2%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Johnson & Johnson seasonality: the next 20 trading days
Over the next 20 trading days from Sep 19, Johnson & Johnson averaged +0.5% across the last 5 years, rising in 2 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −0.8% | 1 of 5 |
| Next 10 trading days | −1.0% | 1 of 5 |
| Next 15 trading days | −0.6% | 1 of 5 |
| Next 20 trading days | +0.5% | 2 of 5 |
| Next 30 trading days | −0.1% | 2 of 5 |
For scale, JNJ’s typical 20-trading-day move in either direction is about 3.4%.
Johnson & Johnson market cap and key statistics
Johnson & Johnson’s market cap is $650.6B, with a P/E ratio of 31 and revenue of $97.93B over the last twelve months.
Valuation
- Market cap
- $650.6B
- P/E ratio
- 31
- Forward P/E
- 20.9
- EPS, TTM
- $8.73
- Gekko Fair Value
- $277.59
Trading
- Volume
- 15.93M
- Avg volume, 20 days
- 6.32M
- 52-week high
- $281.07
- 52-week low
- $173.33
- Shares outstanding
- 2.41B
Financials
- Revenue, TTM
- $97.93B
- Profit margin
- 21.5%
- Return on equity
- 25.7%
- Quarterly earnings growth, YoY
- −0.9%
Risk and income
- Beta
- 0.24
- Typical daily move
- ±2%
- Typical 20-day move
- ±3.4%
- Dividend yield
- 1.96%
Johnson & Johnson stock news this week
Coverage of Johnson & Johnson this week reads positive: 5 positive, 3 neutral and 2 negative headlines.
- Former J&J Unit Beats Claims Its Sunscreen Caused CancerLaw360, Sep 18
- J&J Up 18% in Three Months: Buy, Sell or Hold the Stock?Zacks Investment Research, Sep 18
- Nykredit A S Takes $235.82 Million Position in Johnson & Johnson $JNJDefense World, Sep 18
- Johnson & Johnson $JNJ Shares Sold by Smith Chas P & Associates PA CpasDefense World, Sep 18
- Better Dividend King to Buy and Hold: Johnson & Johnson or Kenvue?The Motley Fool, Sep 17
- PepsiCo elects Johnson & Johnson CEO to board of directorsInvesting.com, Sep 17
Johnson & Johnson peers
Johnson & Johnson’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Accumulation | 15.7% above |
| ABBVAbbVie | Neutral | 22.6% above |
| MRKMerck | Neutral | 7.3% below |
| AZNAstraZeneca | Neutral | 41.0% below |
| PFEPfizer | Neutral | 9.8% below |
| VRTXVertex Pharmaceuticals | Accumulation | 9.7% above |
A peer links to its own page where one exists.
Johnson & Johnson stock FAQ
What is Johnson & Johnson’s market cap?
Johnson & Johnson’s market cap is $650.6B at the Sep 18, 2026 close of $269.99, with 2.41B shares outstanding. The shares trade on a P/E ratio of 31.
What is the Johnson & Johnson stock forecast?
The consensus analyst 12-month price target for Johnson & Johnson is $277.91, +2.9% from the last close. Of the 18 firms that rated the stock in the last 90 days, 14 rate it a buy, 4 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Johnson & Johnson stock overvalued or undervalued?
On Gekko’s estimate Johnson & Johnson is about fair value: the Sep 18, 2026 close of $269.99 is 2.7% below Gekko Fair Value of $277.59. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Johnson & Johnson report earnings next?
Johnson & Johnson is expected to report on Oct 13, 2026, before the market opens (23 days away). Analysts expect earnings of $2.85 per share on revenue of $25.33B. Johnson & Johnson beat the earnings estimate in 7 of its last 8 reports, moving 1.3% on average across the report.
What is Johnson & Johnson’s 52-week high and low?
Johnson & Johnson’s 52-week high is $281.07 and its 52-week low is $173.33; it closed at $269.99 on Sep 18, 2026, +52.4% over the past year.
Is Johnson & Johnson stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 1 of the 5 items with data read as supportive (trend), 3 as mixed (gekkoindex, fair value and seasonality) and 1 as a headwind (earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
Prices and signals update after every US market close; the GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Johnson & Johnson the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,349 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.